ADD/ADHD News

NEW ORLEANS — Data presented here indicated efficacy and safety of Mydayis, a once-daily mixed salts of a single-entity amphetamine product, for ADHD in adults.

The 30th annual Psych Congress will take place in New Orleans from Saturday, Sept. 16 through Tuesday, Sept. 19.

ADHD may primarily be a problem associated with abnormal circadian sleep, according to an expert at the European College of Neuropsychopharmacology Congress.

ADHD symptom type and gender influenced risk for smoking, according to recent findings that indicated greater association between ADHD and smoking outcomes in females.

Children with ADHD, oppositional defiant disorder or conduct disorder, and depression were significantly more likely to develop subsequent substance-related disorders, according to recent findings.

Recent findings did not indicate a causal association between methylphenidate treatment and suicide attempts.

A panel of clinicians and researchers recently published revised treatment recommendations for management of Pediatric Acute Onset Neuropsychiatric Syndrome and Pediatric Autoimmune Neuropsychiatric Syndrome Associated with Streptococcal Infection.

Impax Laboratories recently announced receipt of an AB therapeutic equivalent rating and final FDA approval for its abbreviated New Drug Application for a generic version of extended-release Concerta for ADHD.

ADHD medication treatment was not associated with increased risk for substance-related problems in adolescence or adulthood, according to study results.

Impax Laboratories recently announced the FDA approval and launch of its generic version of Focalin XR extended-release capsules CII at 25-mg and 35-mg strengths.